eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2021
vol. 13
 
Share:
Share:
more
 
 
abstract:
Case report

High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases

Łukasz Raszewski
1
,
Artur J. Chyrek
2
,
Magdalena Marciniak
3
,
Wojciech M. Burchardt
2, 4
,
Grzegorz M. Bielęda
4, 5
,
Adam Chicheł
2

1.
Radiotherapy Department III, Greater Poland Cancer Centre, Poznan, Poland,
2.
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland
3.
Radiotherapy Department II, Greater Poland Cancer Centre, Poznan, Poland
4.
Electroradiology Department, Poznan University of Medical Sciences, Poznan, Poland
5.
Medical Physics Department, Greater Poland Cancer Centre, Poznan, Poland
J Contemp Brachytherapy 2021; 13, 3: 331–337
Online publish date: 2021/05/07
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The aim of this study was to present a case of complete clinical response of renal clear cell carcinoma cutaneous metastases after high-dose-rate surface brachytherapy (HDR sBT).

Material and methods
An 81-year-old female diagnosed with stage IV clear cell renal carcinoma reported to our center with painful relapse of two cutaneous metastases after a previous metastasectomy. The patient was disqualified from systemic therapy due to comorbidities, and qualified to attempt a treatment using HDR sBT. The unit equipped with an iridium-192 source was used to deliver 36 Gy/6 Gy in 6 fractions twice weekly. Overall treatment time was 18 days.

Results
Two weeks after HDR sBT, complete response was observed in one irradiated location, while the partial response was observed in the latter. EORTC grade 1 skin toxicity was reported in both irradiated fields. Three and five months after the treatment, the patient presented complete response and pain relief in both locations with no signs of relapse. The patient remained in palliative care and died seven months after the treatment due to sudden cardiac death.

Conclusions
HDR sBT can be a valuable treatment option for cutaneous metastatic renal cell carcinoma, especially for patients with significant comorbidities. The treatment provided was associated with low toxicity and excellent clinical outcome.

keywords:

renal cell carcinoma, skin metastases, palliative therapy, HDR brachytherapy

 
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe